Hyun, Jae-Won
Kim, Ki Hoon
Kim, Su-Hyun
Kim, Ho Jin
Funding for this research was provided by:
National Cancer Center, Korea (2211610)
Article History
Received: 16 September 2022
Accepted: 3 December 2022
First Online: 10 December 2022
Declarations
:
: Ki Hoon Kim reports no financial disclosures. Jae-Won Hyun has received grants from the National Cancer Center and National Research Foundation of Korea. Su-Hyun Kim has lectured, consulted, and received honoraria from Bayer Schering Pharma, Biogen, Genzyme, Merck Serono, and UCB, and received a grant from the National Research Foundation of Korea. Ho Jin Kim has received a grant from the National Research Foundation of Korea, research support from Aprilbio and Eisai, consultancy/speaker fees from Alexion, Aprilbio, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, MDimune, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, UCB, and Viela Bio, and is a co-editor for the Multiple Sclerosis Journal and an associated editor for the Journal of Clinical Neurology.
: This study was approved by the Institutional Review Board of NCC (No. NCC 2022–0142), and the requirement for patient informed consent was waived due to the use of anonymized data.